Sinoltech: SAL0140 has received clinical trial approval.

Xinlitai announcement, the company has received the "Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the company to conduct clinical trials of the innovative small molecule drug SAL0140 tablets for the treatment of uncontrolled hypertension. SAL0140 is an aldosterone synthase inhibitor with independent intellectual property rights developed by the company, intended for indications including uncontrolled hypertension. Preclinical studies have shown that SAL0140 selectively inhibits the activity of aldosterone synthase, achieving inhibition of aldosterone synthesis without affecting the levels of cortisol. In a hypertension monkey model, SAL0140 can significantly inhibit the production of aldosterone, with once daily dosing achieving effective and stable blood pressure control.